Date: 2016-12-21
Type of information: Development agreement
Compound: companion diagnostic tests for cancer patients
Company: Bayer Healthcare (Germany) Leica Biosystems (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism: companion diagnostic. These companion diagnostic tests will be based on tissue samples using RNAscope® (a multiplex nucleic acid hybridization technology). This in-situ hybridization technology with its proprietary double Z probe design and reagents enable reliable detecting of RNA biomarkers at a single molecule sensitivity with native morphological context for formalin-fixed paraffin-embedded (FFPE) tissue. Leica Biosystems and Advanced Cell Diagnostics have collaborated to automate the RNAscope assay on the Leica Bond instrument platform providing automated analysis.
Disease:
Details: * On December 21, 2016, Bayer has entered into an agreement with Leica Biosystems to collaborate on the development of companion diagnostic tests based on tissue samples using RNAscope® (a multiplex nucleic acid hybridization technology) and immunohistochemistry for cancer patients. These tests aim to use molecular information from the patients to identify the best targeted drugs. The collaboration will focus on Bayer's novel anti-cancer agents. Under the terms of the agreement, the partners will use Leica Biosystems expertise in assay development, regulatory approval and commercialization of companion diagnostic tests based on the automated BOND technology platform for novel targeted anti-cancer therapies developed by Bayer.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
